Quick Solutions On GSK-3 inhibitor Problems

In this 3-year parallel-group study, 50 haemodialysis patients were randomized to either combination therapy with calcium acetate [pills containing 435 mg calcium acetate (110 mg elemental calcium) plus 235 mg magnesium GSK-3 inhibitor carbonate (60 mg elemental magnesium)] or calcium carbonate monotherapy. The dialysate was the same for both groups with calcium of 1.5 mmol/L and magnesium of 0.5 mmol/L. Dose adjustment of both phosphate-binder groups was based on serum calcium and phosphate concentrations and plasma intact parathyroid hormone (iPTH) levels. Combination treatment with magnesium carbonate and calcium acetate resulted in significantly lower serum phosphate and calcium concentrations compared with calcium carbonate monotherapy (both P ankyrin resulted in a significant increase in serum magnesium concentration (P find more and calcium carbonate offered control of serum phosphate that was at least as good as that with calcium acetate alone. The proportion of patients with serum phosphate 0.05). Moreover, this equivalent control was obtained with a significant decrease in mean (��SD) elemental calcium consumption in the magnesium/calcium carbonate group (908 �� 24 mg/day versus 1743 �� 37 mg/day, respectively; P